P552: Clinical factors associated with ustekinumab therapy persistence in a refractory Crohn’s disease cohortECCO'24Year: 2024
Authors: Corcoran, R.(1)*;Breslin, N.(2);Ryan, B.(2);O@E@Connor, A.(2);O@E@Donnell, S.(2);McKiernan, S.(1);MacCarthy, F.(1);Dunne, C.(1);Hartery, K.(1);McNamara, D.(2);Kevans, D.(1);
(1)St James@E@s Hospital, Department of Gastroenterology, Dublin 8, Ireland;(2)Tallaght University Hospital, Department of Gastroenterology, Dublin 24, Ireland;Trinity Academic Gastroenterology Group (TAAG)
P553: The safety and efficacy of adalimumab 80mg weekly as maintenance therapy in pediatric Crohn’s DiseaseECCO'24Year: 2024
Authors: Cohen-Sela , E.(1);Weintraub , Y.(1);Yerushalmy-Feler , A.(2);Orlanski-Meyer , E.(3);Nassar , R.(4);Magen-Rimon , R.(5);Shamir , R.(1);Shouval , D.S.(1);Matar , M.(1)*;
(1)Schneider Children@E@s Medical Center and the Faculty of Medicine- Tel Aviv University, Institute of Gastroenterology- Nutrition and Liver Diseases, Petach Tikva, Israel;(2)Dana-Dwek Children@E@s Hospital, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(3)Shaare Zedek Medical Center, The Institute of Gastroenterology- Nutrition and Liver Diseases, Jerusalem, Israel;(4)Soroka Medical Center, Pediatric Gastroenterology Unit, Beer Sheva, Israel;(5)Rambam Medical Center, Pediatric Gastroenterology Unit, Haifa, Israel;
P554: Assessment of corticosteroid prescribing trends and appropriateness for management of Inflammatory Bowel Disease in a secondary care centre in New ZealandECCO'24Year: 2024
Authors: Hajelssedig, O.(1,2)*;Clark, E.(1);Edward, P.(1);Kenrick, K.(3);Inns, S.(2);
(1)Nelson Marlborough Health, Medicine, Nelson, New Zealand;(2)University of Otago, Medicine, Wellington, New Zealand;(3)University of Otago, Department of General Practice and Rural Health- Dunedin School of Medicine, Dunedin, New Zealand;
P555: Switching from intravenous vedolizumab to subcutaneous maintains clinical remission even in intensified patients with Inflammatory Bowel Disease. One year follow-up.ECCO'24Year: 2024
Authors: Andres Pascual, L.(1);Arias García , L.(2);Saiz Chumillas , R.M.(2);Chivato Martín-Falquina, I.(2);Sicilia Aladren, B.(2)*;
(1)Hospital Universitario de Burgos, Gastroenterology., Burgos, Spain;(2)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;
P556: Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn’s disease: A systematic review and network meta-analysisECCO'24Year: 2024
Authors: Sinopoulou, V.(1);Gordon, M.(2);Vuyyuru, S.(3)*;Darie, A.M.(3);Radford, S.(4);Shale, M.(3);Moran , G.(5);
(1)University of Central Lancashire, UCLan Cochrane Gut Group, Preston, United Kingdom;(2)University of Central Lancashire, Paediatrics, Preston, United Kingdom;(3)Nottingham University Hospitals- NHS trust, Gastroenterology, Nottingham, United Kingdom;(4)University of Nottingham, Gastroenterology, Nottingham, United Kingdom;(5)Nottingham University Hospitals NHS trust- Nottingham- UK- Nottingham NIHR Biomedical Research Centre- Nottingham- UK- Translational medical sciences- School of Medicine- Faculty of Medicine and Health science- University of Nottingham- UK, Gastroenterology, Nottingham, United Kingdom;
P557: Data communication practices for reporting health care outcomes to improve quality of care: A scoping reviewECCO'24Year: 2024
Authors: Ali, M.(1)*;Visser, E.(2);West, R.(2);Noord, D.V.(2);Woude, C.J.V.D.(3);Deen, W.V.(1);
(1)Erasmus School of Health Policy & Management- Erasmus University Rotterdam, Health Technology Assessment, Rotterdam, The Netherlands;(2)Franciscus Gasthuis & Vlietland, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands;(3)Erasmus MC-University Medical Centre, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands;
P558: Clinical Effectiveness and Safety of Vedolizumab vs. Infliximab in Biologic-Naïve Ulcerative Colitis Patients: A Brazilian Real-World Multicentric Observational StudyECCO'24Year: 2024
Authors: Ferreira, S.(1)*;Chebli, J.M.F.(2);Parra, R.(3);Yukie Sassaki, L.(4);de Mello, M.K.(5);Luporini, R.L.(6);Chebli, L.A.(7);Firmino Nóbrega, F.J.(8);da Silva, B.C.(9);Dutra, R.D.M.(4);de Oliveira Vasconcelos, J.R.(1);Moraes Sales, M.P.(2);Féres, O.(10);Parente, J.M.L.(11);Troncon, L.E.D.A.(12);
(1)Hospital das Clínicas- Ribeirão Preto Medical School, Medicine, Ribeirão Preto, Brazil;(2)Division of Gastroenterology- Federal University of Juiz de Fora, Medicine, Juiz de Fora, Brazil;(3)Hospital das Clínicas- Ribeirão Preto Medical School, Surgery and Anatomy, Ribeirão Preto, Brazil;(4)São Paulo State University Unesp- Medical School, Internal Medicine, Botucatu, Brazil;(5)University of Vale do Itajaí, Medicine, Itajaí, Brazil;(6)Federal University of São Carlos UFSCar, Medicine, São Carlos, Brazil;(7)Division of Gastroenterology- Federal University of Juiz de Fora, Medicine, Juiz de Forra, Brazil;(8)Lauro Wanderley Hospital- Federal University of Paraíba, Gastroenterology, João Pessoa, Brazil;(9)Hospital da Bahia, Gastroenterology, Salvador, Brazil;(10)Ribeirão Preto Medical School- University of São Paulo, Surgery and Anatomy, Ribeirão Preto, Brazil;(11)Faculty of Medicine of the Federal University of Piauí, Gastroenterology, Teresina, Brazil;(12)Ribeirão Preto Medical School- University of São Paulo, Medicine, Ribeirão Preto, Brazil;
P559: Descriptive observational pilot study about the use of Virtual Reality (VR) in patients with Inflammatory Bowel Disease (IBD) and biological treatmentECCO'24Year: 2024
Authors: Díaz Molina, R.J.(1)*;Comesaña Castellar, C.(1);Crespi Rigo, J.(2);Radu Tomsa, C.(2);Quesada Bauzá, P.(2);Porcel Corral, I.(2);Ginard Vicens, D.(1);
(1)Hospital Universitario Son Espases, Gastroenterology, Palma De Mallorca, Spain;(2)University of the Balearic Islands, Faculty of Pedagogy, Palma de Mallorca, Spain;
P560: The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel diseaseECCO'24Year: 2024
Authors: Ivány, E.(1)*;Farkas, B.(1);Resál, T.(1);Bacsur, P.(1);Bálint, A.(1);Farkas, K.(1);Molnár, T.(1);
(1)Szent-Györgyi Albert Medical Centre- University of Szeged, Department of Internal Medicine, Szeged, Hungary;
P561: Reasons for low use of topical 5-ASA formulations in patients treated for ulcerative colitis: comparison of doctors and patients perspectivesECCO'24Year: 2024
Authors: PittetPhD, V.(1)*;Rogler, G.(2);Seibold, F.(3);
(1)Center for Primary Care and Public Health - University of Lausanne, Epidemiology and Health Services, Lausanne, Switzerland;(2)Usz, Dpt Gastroenterology, Zurich, Switzerland;(3)Intesto, Centre Fribourgeois de Gastroentérologie, Fribourg, Switzerland;
P562: Safety and persistence oh the first JAK inhibitor Tofacitinib in patients with ulcerative colitisECCO'24Year: 2024
Authors: González Chávez, J.(1);Santos Fagundo, A.(1);Ceballos Santos, D.(2);Calzado Gómez, G.(3);González Pérez, Y.(3);Morales León, V.(4);Otazo Pérez, S.M.(3);Hernandez Camba, A.(5)*;
(1)Hospital Universitario Nuestra Señora de Candelaria, Pharmacy, Santa Cruz de Tenerife, Spain;(2)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology, Las Palmas de Gran Canaria, Spain;(3)Hospital Universitario de Canarias, Pharmacy, La Laguna, Spain;(4)Hospital Universitario de Gran Canaria Dr. Negrín, Pharmacy, Las Palmas de Gran Canaria, Spain;(5)Hospital Universitario Nuestra Señora de Candelaria, Department of Gastroenterology, Santa Cruz de Tenerife, Spain;
P563: Nutritional screening in patients with inflammatory bowel disease: a challenge in the timely diagnosis of malnutrition and sarcopenia.ECCO'24Year: 2024
Authors: Parra Izquierdo, L.V.(1)*;Orduz-Diaz, G.(2);Frías-Ordoñez, J.(3);Hoyos-Rondon, S.(4);Reatiga-Pedraza, A.(2);Sarmiento-Navarro, J.(2);Bohorquez, L.E.(1);Cano, D.F.(1);Pinto, O.(1);Duarte, A.(1);Florez-Sarmiento, C.(1);Cuadros, C.(5);Garces, J.(5);Acevedo, J.J.(6);Barco, A.G.(7);Flechas-Amaya, S.M.(8);
(1)Hospital Internacional de Colombia- Bucaramanga- Bucaramanga- Colombia., Gastroenterology, Bucaramanga, Colombia;(2)Hospital Internacional de Colombia- Bucaramanga- Bucaramanga- Colombia., Nursing, Bucaramanga, Colombia;(3)National University of Colombia, Gastroenterology, Bogotá, Colombia;(4)Hospital Internacional de Colombia- Bucaramanga- Bucaramanga- Colombia., General Physician, Bucaramanga, Colombia;(5)Hospital Internacional de Colombia- Bucaramanga- Bucaramanga- Colombia., Pediatric Gastroenterology, Bucaramanga, Colombia;(6)Hospital Internacional de Colombia- Bucaramanga- Bucaramanga- Colombia., Gastrointestinal Surgery, Bucaramanga, Colombia;(7)Hospital Internacional de Colombia- Bucaramanga- Bucaramanga- Colombia., Coloproctology, Bucaramanga, Colombia;(8)Hospital Internacional de Colombia- Bucaramanga- Bucaramanga- Colombia., Nutrition, Bucaramanga, Colombia;
P564: Surgical treatment of jejuno-ileal Crohn’s disease. Results from the The JejUno Ileal Crohn@E@s disEase (JUICE) international, multicentric, observational study.ECCO'24Year: 2024
Authors: Baldi, C.(1)*;Mineccia, M.(2);Ferrero, A.(2);Di Benedetto, M.(3);Spinelli, A.(3);Scarpa, M.(4);Angriman, I.(4);Cricrì, M.(5);Luglio, G.(5);Colombo, F.(6);Danelli, P.(7);Bislenghi, G.(8);D@E@Hoore, A.(8);Nasasra, A.(9);Warusavitarne, J.(9);Manzo, C.A.(10);Celentano, V.(10);Marti-Gallostra, M.(11);Espin Basany, E.(11);Schena, C.A.(12);Pellino, G.(13);De Angelis, N.(12);Rottoli, M.(14);Poggioli, G.(14);Sampietro, G.M.(15);
(1)ASST Rhodense. Rho Memorial Hospital, Department of Surgery. Division of General and HPB Surgery, Milano, Italy;(2)Ospedale Mauriziano, Department of Surgery. Division of General and Oncologic Surgery, Torino, Italy;(3)Humanitas Clinical and Research Center IRCCS, Department of Surgery. Division of Colon and Rectal Surgery, Rozzano, Italy;(4)Università degli Studi di Padova, Dipartimento di Scienze Chirurgiche- Oncologiche e Gastroenterologiche. Division of General Surgery 3, Padova, Italy;(5)Azienda Ospedaliera Universitaria Federico II, Dipartimento ad Attività Integrata Medico-Chirurgico di Patologie dell’Apparato Digerente. Unità di Chirurgia Endoscopica., Napoli, Italy;(6)ASST Fatebenefratelli - Sacco, Department of Surgery. IBD Surgical Unit, Milano, Italy;(7)ASST Fatebenefratelli - Sacco, Department of Surgery. Division of General Surgery, Milano, Italy;(8)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;(9)London North West University Healthcare NHS Trust, St Marks National Bowel Hospital, London, United Kingdom;(10)Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom;(11)Hospital Universitari Vall d’Hebron, Servei Cirurgia General i Digestiva. Unitat Coloproctologia., Barcelona, Spain;(12)Beaujon University Hospital, Colorectal and Digestive Surgery Unit - DIGEST Department, Paris, France;(13)Università degli Studi della Campania ‘Luigi Vanvitelli@E@, Department of Advanced Medical and Surgical Sciences, Naples, Italy;(14)Alma Mater Studiorum University of Bologna. Sant@E@Orsola Hospital., Department of Medical and Surgical Sciences, Bologna, Italy;(15)ASST Rhodense - Rho Memorial Hospital, Department of Surgery- Division of General and HPB Surgery, Rho- Milano, Italy;
P565: Capillary blood based self-collection device for infliximab therapeutic drug monitoringECCO'24Year: 2024
Authors: Law, C.(1)*;Djalal, A.(1);Hopkins, M.(1);Trick, D.(1);Kang, D.(2);Brady, K.(2);Tucker, D.(2);Everts-van der Wind, A.(2);Dervieux, T.(2);Colombel, J.F.(1);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Prometheus Labs Inc, Research and development, San Diego, United States;
P566: Maintenance vedolizumab treatment in pediatric IBD: 54-week follow-up of the prospective multicenter VEDOKIDS studyECCO'24Year: 2024
Authors: Atia, O.(1);Shavit-Brunschwig, Z.(1);Focht, G.(1);Lev-Tzion, R.(1);Stein, R.(2);Broide, E.(3);Urlep, D.(4);Hyams, J.(5);Weiss, B.(6);Aloi, M.(7);Assa, A.(1);Russell, R.K.(8);Turner, D.(1)*;
(1)Shaare Zedek Medical Center- Jerusalem- Israel, Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Children’s Hospital of Philadelphia- Philadelphia- PA- USA, Division of Gastroenterology- Hepatology and Nutrition, Philadelphia, United States;(3)Shamir Medical Center- Be’er Ya’akov- Israel, Division of Digestive Diseases, Be@E@er Yaakov, Israel;(4)University Children’s Hospital of the University Medical Centre Ljubljana- Ljubljana- Slovenia, Pediatric Gastroenterology and Liver Unit, Ljubljana, Slovenia;(5)Connecticut Children’s Medical Center- Hartford- CT- USA, Clinic of Pediatrics, Hartford, United States;(6)The Edmond & Lily Safra Children’s Hospital- Sheba Medical Center- Tel HaShomer- Israel, Pediatric Gastroenterology and Nutrition, Tel HaShomer, Israel;(7)Sapienza University of Rome- Rome- Italy, Pediatric Gastroenterology- Hepatology and Nutrition Institute, Rome, Italy;(8)The Royal Hospital for Children & Young People- Edinburgh- UK, Division of Pediatric Gastroenterology, Edinburgh, United Kingdom;
P567: Impact of recent thiopurine use on ozanimod safety in patients with ulcerative colitis: a post hoc analysis of the phase 3 True North studyECCO'24Year: 2024
Authors: Battat, R.(1)*;Panaccione, R.(2);Hart, A.(3);Hisamatsu, T.(4);Ahmad, H.A.(5);Osterman, M.T.(5);Wu, H.(5);Jain, A.(5);Rosen, M.(5);Siegmund, B.(6);
(1)Division of Gastroenterology and Hepatology- Centre Hospitalier de l@E@Université de Montréal- University of Montreal, Gastroenterology and Hepatology, Montreal, Canada;(2)Inflammatory Bowel Disease Clinic- IBD Research- University of Calgary, Inflammatory Bowel Disease, Calgary- AB, Canada;(3)St Mark@E@s Hospital and Imperial College, Gastroenterology, London, United Kingdom;(4)Kyorin University School of Medicine, Gastroenterology and Hepatology, Tokyo, Japan;(5)Bristol Myers Squibb, n/a, Princeton, United States;(6)Department of Gastroenterology- Infectious Diseases and Rheumatology- Charité – Universitätsmedizin Berlin, Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;
P568: Clinical relevance of baseline and change in Urgency Numeric Rating Scale score for mirikizumab treatment for Ulcerative ColitisECCO'24Year: 2024
Authors: Clemow, D.(1)*;Dubinsky, M.C.(2);Baygani, S.(1);Sands, B.E.(3);Keohane, A.(4);Danese, S.(5);Travis, S.(6);Schreiber, S.(7);Walsh, A.(8);Hibi, T.(9);Hunter Gibble, T.(1);Moses, R.(1);
(1)Eli Lilly and Company, Eli Lilly and Company, Indianapolis, United States;(2)Mount Sinai Hospital, Division of Pediatric GI and Nutrition, New York, United States;(3)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(4)HaaPACS GmBH, Biostatistics, Schriesheim, Germany;(5)Vita-Salute San Raffaele University - IRCCS San Raffaele Hospital, Gastroenterology and Endoscopy, Milan, Italy;(6)University of Oxford, Kennedy Institute and Translational Gastroenterology, Oxford, United Kingdom;(7)University Hospital Schleswig-Holstein, Department of Internal Medicine, Kiel, Germany;(8)University of Oxford, University Hospitals NHS Foundation Trust, Oxford, United Kingdom;(9)Kitasato University- Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;
P569: Persistence and safety of upadacitinib in Crohn’s disease and ulcerative colitis in real life: results from a Spanish nationwide studyECCO'24Year: 2024
Authors: García, M.J.(1)*;Brenes, Y.(2);Vicuña, M.(3);Bermejo, F.(4);Sierra-Ausín, M.(5);Polo Cuadro, C.(6);Arroyo, M.T.(7);Martínez Montiel, P.(8);Villoria, A.(9);Pérez-Calle, J.L.(10);Hernandez, V.(11);Piñero, A.(12);Carrillo-Palau, M.(13);Martín-Arranz, M.D.(14);Miranda-Bautista, J.(15);Pajares, R.(16);Arranz Hernández, L.(17);Bejarano, A.(18);Guardiola, J.(19);Iyo, E.(20);Muñoz-Villafranca, C.(21);Talavera, A.(22);Alonso-Galán, H.(23);Barreiro-de Acosta, M.(24);Bosca-Watts, M.(25);Vázquez Rey, T.(26);Echarri, A.(27);Rodríguez-Grau, M.D.C.(28);Gutiérrez, A.(29);Huguet, J.M.(30);López-Martín, M.C.(31);Mesonero, F.(32);Pérez-Martínez, I.(33);Plaza, R.(34);Ramírez de la Piscina, P.(35);Gisbert*, J.P.(2);Chaparro*, M.(2);
(1)Hospital Universitario Marqués de Valdecilla- Grupo de Investigación Clínica y Traslacional en Enfermedades Digestivas- Instituto de Investigación Sanitaria Valdecilla IDIVAL- Universidad de Cantabria, Gastroenterology Department, Santander- Cantabria, Spain;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department, Madrid, Spain;(3)Complejo Hospitalario de Navarra, Gastroenterology Department, Pamplona, Spain;(4)Hospital Universitario de Fuenlabrada, Gastroenterology Department, Fuenlabrada- Madrid, Spain;(5)Complejo Asistencial Universitario de León, Gastroenterology Department, León, Spain;(6)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(7)Hospital Clínico Universitario “Lozano Blesa”- IIS Aragón and CIBERehd, Gastroenterology Department, Zaragoza, Spain;(8)Hospital Universitario 12 de Octubre, Gastroenterology Department, Madrid, Spain;(9)Consorci Corporació Sanitària Parc Taulí- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department, Sabadell, Spain;(10)Hospital Universitario Fundación Alcorcón, Gastroenterology Department, Madrid, Spain;(11)Hospital Álvaro Cunqueiro- Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur- SERGAS-UVIGO, Gastroenterology Department, Vigo, Spain;(12)Hospital Universitario de Jerez de la Frontera, Gastroenterology Department, Jerez de la Frontera, Spain;(13)Hospital Universitario de Canarias, Gastroenterology Department, La Laguna, Spain;(14)Hospital Universitario La Paz- Instituto de Investigación Sanitaria La Paz IdiPaz- Universidad Autónoma de Madrid, Gastroenterology Department, Madrid, Spain;(15)Hospital Universitario Gregorio Marañón- Instituto de Investigación Sanitaria Gregorio Marañón IiSGM, Gastroenterology Department, Madrid, Spain;(16)Hospital Universitario Infanta Sofía, Gastroenterology Department, San Sebastián de los Reyes, Spain;(17)Hospital Universitario Nuestra Señora de la Candelaria, Gastroenterology Department, Santa Cruz de Tenerife, Spain;(18)Hospital Juan Ramón Jiménez, Gastroenterology Department, Huelva, Spain;(19)Bellvitge University Hospital- Bellvitge Biomedical Research Institute-IDIBELL- University of Barcelona, Gastroenterology Department, L@E@Hospitalet de Llobregat- Barcelona, Spain;(20)Hospital Comarcal de Inca, Gastroenterology Department, Inca, Spain;(21)Hospital Universitario de Basurto, Gastroenterology Department, Bilbao, Spain;(22)Hospital Infanta Elena, Gastroenterology Department, Huelva, Spain;(23)Hospital Universitario Donostia- Instituto Biogipuzkoa, Gastroenterology Department, San Sebastián, Spain;(24)Hospital Clínico Universitario de Santiago, Gastroenterology Department, Santiago de Compostela, Spain;(25)Hospital Clínico Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(26)Hospital Universitario de A Coruña, Gastroenterology Department, A Coruña, Spain;(27)Hospital Arquitecto Marcide, Gastroenterology Department, Ferrol- La Coruña, Spain;(28)Hospital Universitario de Henares, Gastroenterology Department, Coslada, Spain;(29)Hospital General Universitario Dr Balmis de Alicante and Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL- CIBERehd, Gastroenterology Department, Alicante, Spain;(30)Hospital General Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(31)Hospital Universitario Infanta Elena, Gastroenterology Department, Valdemoro- Madrid, Spain;(32)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(33)Hospital Universitario Central de Asturias- Oviedo- Spain- Diet- Microbiota and Health Group. Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Department, Oviedo, Spain;(34)Hospital Universitario Infanta Leonor, Gastroenterology Department, Madrid, Spain;(35)Hospital Universitario Vitoria-Gastéiz, Gastroenterology Department, Vitoria, Spain;*Equally contribution as senior authors.
P570: Efficacy and safety of Adalimumab in Very Early-onset IBD- A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN.ECCO'24Year: 2024
Authors: Weintraub, Y.(1,2)*;Collen Veit , L.(3);Hussey , S.(4);Mitrova, K.(5,6);Croft, N.M.(7,8);Kang, B.(9);Granot, M.(2,10);D@E@Arcangelo, G.(11);Spencer, E.(12);Kolho, K.L.(13);Yeh , P.J.(14);Sladek, M.(15);Scarallo, L.(16,17);Palomino Pérez, L.(18);Afzal, N.(19);de Laffolie, J.(20);Miele, E.(21);Bramuzzo, M.(22);Olén, O.(23,24);Russell, R.(25);Rohani, P.(26);Tzivinikos, C.(27);Urlep, D.(28);van Rheenen, P.F.(29);de Ridder, L.(30);Yogev, D.(31,32);Schneider , A.M.(33);Cohen, S.(2,34);Garcia Romero, R.(35);Dipasquale, V.(36);Uhlig, H.(14,37,38);Shouval S., D.(1,2);
(1)Schneider Children@E@s Medical, Institute of Gastroenterology- Nutrition and Liver Diseases, Petach Tikva, Israel;(2)Tel Aviv University- Tel Aviv- Israel, Faculty of Medicine, Tel Aviv, Israel;(3)Boston Children@E@s Hospital and Harvard Medical School- Boston-MA-USA, Division of Gastroenterology- Hepatology- and Nutrition- Department of Pediatrics-, Boston, United States;(4)Children@E@s Health Ireland- UCD and RCSI- Dublin- Ireland, Pediatrics, Dublin, Ireland;(5)2nd Faculty of Medicine- Charles University and University Hospital Motol- Prague- Czech Republic, Department of Paediatrics-, Prague, Czech Republic;(6)ISCARE and First Faculty of Medicine- Charles University- Prague- Czech Republic., the Clinical and Research Centre for Inflammatory Bowel Disease, Prague, Czech Republic;(7)Queen Mary University of London- London- UK., Faculty of Medicine- Blizard Institute, London, United Kingdom;(8)Royal London Children@E@s Hospital- Barts Health NHS Trust- London- UK., Paediatric Gastroenterology-, London, Israel;(9)School of Medicine- Kyungpook National University- Daegu- Korea, Department of Pediatrics-, Daegu, Korea- Republic Of;(10)Edmond and Lily Safra Children’s Hospital- Sheba Medical Center- Tel Hashomer- Israel, Pediatric Gastroenterology and Nutrition Unit-, Ramat gan, Israel;(11)Sapienza University of Rome- Umberto I Hospital, Department of Women@E@s and Children@E@s Health- Pediatric Gastroenterology and Liver Unit-, Rome, Italy;(12)Icahn School of Medicine- Mount Sinai- New York- USA, Division of Pediatric Gastroenterology & Nutrition- Department of Pediatrics-, New York, United States;(13)Children@E@s Hospital- University of Helsinki and HUS Helsinki- Finland., Department of Pediatric Gastroenteroloy, Helsinki, Finland;(14)University of Oxford- Oxford- UK, Translational Gastroenterology Unit, Oxford, United Kingdom;(15)Jagiellonian University- Cracow- Poland., Polish-American Children@E@s Hospital-, Cracow, Poland;(16)Meyer Children Hospital IRCCS- Florence- Italy, Gastroenterology and Nutrition Unit, Florence, Italy;(17)University of Florence- Florence- Italy, Department of NEUROFARBA, Florence, Italy;(18)Hospital Infantil Universitario Niño Jesús- Madrid- Spain, Gastroenterology and Nutrition Department, Madrid, Spain;(19)Southampton Children@E@s Hospital- Southampton- United Kingdom, Department of Paediatric Gastroenterology, Southampton, United Kingdom;(20)Justus-Liebig-University- Giessen- Germany, General Pediatrics & Pediatric Gastroenterology-, Giessen, Germany;(21)Section of Pediatrics University of Naples @D@Federico II@D@, Department of Translational Medical Science, Naples, Italy;(22)IRCCS @D@Burlo Garofolo-@D@ Trieste- Italy., Institute for Maternal and Child Health, Trieste, Italy;(23)Karolinska Institutet- Stockholm- Sweden, Division of Clinical Epidemiology- Department of Medicine Sona-, Stockholm-, Sweden;(24)Pediatric Gastroenterology and Nutrition Unit- Sachs@E@ Children@E@s Hospital- Stockholm- Sweden, Pediatric Gastroenterology and Nutrition Unit, Stockholm, Sweden;(25)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Edinburgh, United Kingdom;(26)Children@E@s Medical Center- Pediatrics Center of Excellence- Tehran University of Medical Sciences- Tehran- Iran., Pediatric Gastroenterology and Hepatology Research Center, Tehran, Iran- Islamic Republic Of;(27)Al Jalila Children@E@s Specialty Hospital- Mohammed Bin Rashid University- Dubai Medical College- Dubai- United Arab Emirates, Paediatric Gastroenterology Department, Dubai, United Arab Emirates;(28)Children@E@s Hospital- University Medical Centre Ljubljana- Ljubljana- Slovenia., Department of Gastroenterology- Hepatology and Nutrition, Ljubljana, Slovenia;(29)Beatrix Children@E@s Hospital, Department of Pediatric Gastroenterology- Hepatology and Nutrition-, Groningen, Netherlands Antilles;(30)Erasmus University Medical Center Sophia Children@E@s Hospital- Rotterdam- Netherlands, Department of Paediatric Gastroenterology, Rotterdam, Netherlands Antilles;(31)Shaare Zedek Medical Center- Jerusalem- Israel, Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition-, Jerusalem, Israel;(32)The Hebrew University of Jerusalem- Israel, Faculty of Medicine, Jerusalem, Israel;(33)Paracelsus Medical University- Salzburg- Austria., Department of Pediatrics, Salzburg, Austria;(34)Dana-Dwek Children’s Hospital- Tel Aviv Sourasky Medical Center- Tel Aviv- Israel, Pediatric Gastroenterology Institute-, Tel Aviv, Israel;(35)Miguel Servet Hospital. Zaragoza. Spain, Pediatric Gastroenterology and Nutrition Unit., Zaragoza, Spain;(36)University Hospital @D@G. Martino@D@- Messina- Italy, Pediatric Gastroenterology and Cystic Fibrosis Unit- Department of Human Pathology in Adulthood and Childhood @D@G. Barresi@D@-, Messina, Italy;(37)University of Oxford- Oxford- UK, Biomedical Research Centre, Oxford, United Kingdom;(38)University of Oxford- Oxford- UK., Department of Paediatrics, Oxford, United Kingdom;
P571: The Effect of NLRX1 Activation on Eosinophils in Ulcerative Colitis and Inflammation: Translational Learnings Across Diseases and from Mouse to HumanECCO'24Year: 2024
Authors: Verstockt, B.(1)*;Dubinsky, M.(2);Peyrin-Biroulet, L.(3);Mosig, R.(4);Cataldi, F.(5);Vermeire, S.(1);
(1)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology- Department of Chronic Diseases and Metabolism, Leuven, Belgium;(2)Mount Sinai Kravis Children@E@s Hospital- Icahn School of Medicine Mount Sinai, Division of Pediatric Gastroenterology and Nutrition, New York, United States;(3)Nancy University Hospital- University of Lorraine- Paris IBD center- McGill University Health Centre, Department of Gastroenterology- INSERM- NGERE- INFINY Institute- FHU-CURE- Groupe Hospitalier privé Ambroise Paré - Hartmann-Division of Gastroenterology and Hepatology, Vandoeuvre-les-Nancy, France;(4)Landos Biopharma- Inc, Corporate Development, Blacksburg, United States;(5)Landos Biopharma- Inc, Clinical, Boston, United States;